Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 3/20 | 0.46 |
| ▸ | HRH1 | P35367 | 3/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL470992 | 0.90 | EPHX2 (0.47) | HRH2HRH1EPHX2USP2SMN1; SMN2 | |
| SCHEMBL20873847 | 0.85 | USP2 (0.53) | EPHX2USP2SMN1; SMN2TLR8CHRM2 | |
| SCHEMBL16810242 | 0.84 | EPHX2 (0.47) | HRH2HRH1EPHX2USP2SMN1; SMN2 | |
| SCHEMBL8253901 | 0.83 | USP2 (0.51) | EPHX2USP2SMN1; SMN2TLR8CHRM2 | |
| SCHEMBL28698837 | 0.81 | USP2 (0.44) | EPHX2USP2SMN1; SMN2TLR8CHRM2 | |
| SCHEMBL15217025 | 0.81 | TLR8 (0.46) | HRH2HRH1EPHX2USP2SMN1; SMN2 | |
| SCHEMBL8242595 | 0.81 | USP2 (0.61) | EPHX2USP2SMN1; SMN2TLR8CHRM2 | |
| SCHEMBL6476514 | 0.81 | USP2 (0.46) | EPHX2USP2SMN1; SMN2TLR8CHRM2 | |
| SCHEMBL5216019 | 0.80 | USP2 (0.49) | EPHX2USP2SMN1; SMN2TLR8CHRM2 | |
| SCHEMBL214593 | 0.80 | USP2 (0.49) | EPHX2USP2SMN1; SMN2TLR8CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2615089-B1 | Pyrazoloquinoline compounds | ASTELLAS PHARMA INC (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-8822448-B2 | Pyrazoloquinoline compound | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822448-B2 | Pyrazoloquinoline compound | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | PDE9A, PDE5A, PDE2A | HRH2 2709/4885HRH1 3372/4885EPHX2 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.